Acceleron Pharma – Chart Of The Day

The Chart of the Day belongs to Acceleron Pharma (NASDAQ:XLRN). I found the biopharmaceutical stock by using Barchart to sort the Russell 3000 Index stocks first for the highest technical buy signals then I used the Flipchart feature to review the charts. Since the Trend Spotter signaled a buy on 10/28 the stock gained 58.25%.

Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.

(Click on image to enlarge)

The status of Barchart’s Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

  • 100% Barchart technical buy signals
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 8 new highs and up 19.43% in the last month
  • Relative Strength Index 77.47%
  • Barchart computes a technical support level at 43.10
  • Recently traded at 47.25 with a 50 day moving average of 35.83
  • Fundamental factors:

  • Market Cap $1.53 billion
  • Revenue expected to grow 123.30 this year buy decline 21.80% next year’
  • Earnings estimated to increase 31.30% this year but decrease by 64.30% next year
  • Despite these downward projections Wall Street analysts issued 4 strong buy, 1 buy and 2 hold recommendations on the stock
  • The most reliable technical trading strategy has been the 5 day moving average vs. price but that caused a lot of trading. If you have this stock I’d put in a moving stop loss 10% below he recent high to protect gains.

    Print Friendly, PDF & Email

    Author: Travis Esquivel

    Travis Esquivel is an engineer, passionate soccer player and full-time dad. He enjoys writing about innovation and technology from time to time.

    Share This Post On